HRP20100190T1 - Mikročestice koje sadrže analoge somatostatina - Google Patents
Mikročestice koje sadrže analoge somatostatina Download PDFInfo
- Publication number
- HRP20100190T1 HRP20100190T1 HR20100190T HRP20100190T HRP20100190T1 HR P20100190 T1 HRP20100190 T1 HR P20100190T1 HR 20100190 T HR20100190 T HR 20100190T HR P20100190 T HRP20100190 T HR P20100190T HR P20100190 T1 HRP20100190 T1 HR P20100190T1
- Authority
- HR
- Croatia
- Prior art keywords
- microparticles
- microparticles according
- dtrp
- phg
- bzl
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title claims abstract 11
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229940075620 somatostatin analogue Drugs 0.000 title 1
- 229920000642 polymer Polymers 0.000 claims abstract 7
- 239000011159 matrix material Substances 0.000 claims abstract 5
- 150000003839 salts Chemical group 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0326602A GB0326602D0 (en) | 2003-11-14 | 2003-11-14 | Organic compounds |
| GB0406241A GB0406241D0 (en) | 2004-03-19 | 2004-03-19 | Organic compounds |
| PCT/EP2004/012870 WO2005046645A1 (en) | 2003-11-14 | 2004-11-12 | Microparticles comprising somatostatin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100190T1 true HRP20100190T1 (hr) | 2010-06-30 |
Family
ID=34593737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100190T HRP20100190T1 (hr) | 2003-11-14 | 2010-04-01 | Mikročestice koje sadrže analoge somatostatina |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7759308B2 (no) |
| EP (1) | EP1686964B9 (no) |
| JP (1) | JP4682145B2 (no) |
| KR (1) | KR101233892B1 (no) |
| AR (1) | AR047310A1 (no) |
| AT (1) | ATE455537T1 (no) |
| AU (1) | AU2004289055C1 (no) |
| BR (1) | BRPI0416227B8 (no) |
| CA (1) | CA2541944C (no) |
| CY (2) | CY1110293T1 (no) |
| DE (1) | DE602004025271D1 (no) |
| DK (1) | DK1686964T3 (no) |
| EC (1) | ECSP066565A (no) |
| ES (1) | ES2339026T3 (no) |
| HK (1) | HK1093682A1 (no) |
| HR (1) | HRP20100190T1 (no) |
| IL (1) | IL175286A (no) |
| IS (1) | IS8480A (no) |
| LU (1) | LU92701I2 (no) |
| MA (1) | MA28155A1 (no) |
| MX (1) | MXPA06005357A (no) |
| MY (1) | MY158342A (no) |
| NO (2) | NO337172B1 (no) |
| NZ (1) | NZ546788A (no) |
| PE (1) | PE20050581A1 (no) |
| PL (1) | PL1686964T3 (no) |
| PT (1) | PT1686964E (no) |
| RU (1) | RU2404749C2 (no) |
| SI (1) | SI1686964T1 (no) |
| TW (1) | TWI295178B (no) |
| WO (1) | WO2005046645A1 (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| WO2007071395A1 (en) * | 2005-12-22 | 2007-06-28 | Novartis Ag | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
| KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
| US20080287464A1 (en) * | 2007-05-18 | 2008-11-20 | Wright Jeremy C | Depot Formulations |
| PE20090387A1 (es) * | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| AU2009209594A1 (en) * | 2008-01-30 | 2009-08-06 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| US9629798B2 (en) * | 2008-04-03 | 2017-04-25 | Mallinckrodt Pharma Ip Trading D.A.C. | Hemostatic microspheres |
| PT2310042E (pt) | 2008-07-08 | 2013-03-11 | Novartis Ag | Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena |
| US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
| US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
| US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
| US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
| US8569421B2 (en) | 2009-04-23 | 2013-10-29 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
| US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
| US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
| WO2013131879A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
| CN105189643B (zh) | 2012-08-30 | 2019-01-15 | 派诺聚合物技术公司 | 用于水力压裂液的双重机制增稠剂 |
| CA2899349C (en) | 2013-02-04 | 2021-09-21 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
| WO2014164754A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| CN107075015B (zh) | 2014-07-03 | 2019-08-23 | 派诺聚合物技术公司 | 表面活性剂-相容性星形大分子 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| ES2185373T3 (es) * | 1998-07-23 | 2003-04-16 | Sod Conseils Rech Applic | Encapsulacion de peptidos solubles en agua. |
| WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
| EP1240896A3 (en) | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
| ATE252915T1 (de) | 1999-08-18 | 2003-11-15 | Sod Conseils Rech Applic | Formulierung zur verzögerten freisetzung von peptiden |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| WO2003075892A1 (en) * | 2002-03-13 | 2003-09-18 | Novartis Ag | Pharmaceutical microparticles |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
-
2004
- 2004-11-09 MY MYPI20044662A patent/MY158342A/en unknown
- 2004-11-11 AR ARP040104157A patent/AR047310A1/es not_active Application Discontinuation
- 2004-11-12 TW TW093134728A patent/TWI295178B/zh active
- 2004-11-12 WO PCT/EP2004/012870 patent/WO2005046645A1/en active Application Filing
- 2004-11-12 EP EP04797866A patent/EP1686964B9/en active Active
- 2004-11-12 NZ NZ546788A patent/NZ546788A/en unknown
- 2004-11-12 KR KR1020067009270A patent/KR101233892B1/ko active IP Right Grant
- 2004-11-12 MX MXPA06005357A patent/MXPA06005357A/es active IP Right Grant
- 2004-11-12 DK DK04797866.3T patent/DK1686964T3/da active
- 2004-11-12 SI SI200431378T patent/SI1686964T1/sl unknown
- 2004-11-12 CA CA2541944A patent/CA2541944C/en active Active
- 2004-11-12 PT PT04797866T patent/PT1686964E/pt unknown
- 2004-11-12 US US10/579,186 patent/US7759308B2/en active Active
- 2004-11-12 DE DE602004025271T patent/DE602004025271D1/de active Active
- 2004-11-12 RU RU2006120484/15A patent/RU2404749C2/ru active
- 2004-11-12 PE PE2004001111A patent/PE20050581A1/es active IP Right Grant
- 2004-11-12 JP JP2006538808A patent/JP4682145B2/ja active Active
- 2004-11-12 PL PL04797866T patent/PL1686964T3/pl unknown
- 2004-11-12 AU AU2004289055A patent/AU2004289055C1/en active Active
- 2004-11-12 ES ES04797866T patent/ES2339026T3/es active Active
- 2004-11-12 AT AT04797866T patent/ATE455537T1/de active
- 2004-11-12 BR BRPI0416227A patent/BRPI0416227B8/pt active IP Right Grant
-
2006
- 2006-04-27 IL IL175286A patent/IL175286A/en active IP Right Grant
- 2006-05-11 MA MA29019A patent/MA28155A1/fr unknown
- 2006-05-12 EC EC2006006565A patent/ECSP066565A/es unknown
- 2006-05-23 IS IS8480A patent/IS8480A/is unknown
- 2006-06-14 NO NO20062777A patent/NO337172B1/no active Protection Beyond IP Right Term
-
2007
- 2007-01-04 HK HK07100155.4A patent/HK1093682A1/xx unknown
-
2010
- 2010-03-09 CY CY20101100222T patent/CY1110293T1/el unknown
- 2010-04-01 HR HR20100190T patent/HRP20100190T1/hr unknown
- 2010-06-08 US US12/796,132 patent/US8188037B2/en active Active
-
2012
- 2012-04-26 US US13/456,681 patent/US20120214749A1/en not_active Abandoned
-
2015
- 2015-03-26 CY CY2015011C patent/CY2015011I1/el unknown
- 2015-04-29 LU LU92701C patent/LU92701I2/xx unknown
-
2016
- 2016-02-02 NO NO2016003C patent/NO2016003I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100190T1 (hr) | Mikročestice koje sadrže analoge somatostatina | |
| WO2002015877A8 (en) | Methods and compositions for targeted delivery | |
| Jones et al. | Development and mechanical characterization of bioadhesive semi-solid, polymeric systems containing tetracycline for the treatment of periodontal diseases | |
| HRP20210179T1 (hr) | Farmaceutski pripravak za modificirano otpuštanje | |
| BRPI0509659B8 (pt) | processo para a preparação de uma composição de polímero de dispersão aquosa | |
| ATE305774T1 (de) | Überzugs- und bindemittel für arzneimittelformulierungen mit verbesserter lagerstabilität | |
| DK1553927T3 (da) | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger | |
| RS52813B (en) | PHARMACEUTICAL DOSAGE FORMS | |
| CA2220871A1 (en) | Peptide/protein suspending formulations | |
| HRP20110646T1 (hr) | Injektabilna suspenzija aripiprazola | |
| BR0308075A (pt) | Composição de limpeza lìquida isotrópica, método para a preparação de uma composição e método de depositar agente de benefìcio | |
| RU2004137118A (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления | |
| BR0211736A (pt) | Formulação para suspensão oral estabilizada | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| ATE531368T1 (de) | Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung | |
| BR0318049A (pt) | Processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo | |
| EP2258351A3 (en) | Granules containing lansoprazole in large amount | |
| BR0316310A (pt) | Composições farmacêuticas tendo um veìculo modificado | |
| JP2007511482A5 (no) | ||
| HRP20161785T1 (hr) | Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica | |
| HRP20120483T1 (hr) | Formulacije peg interferona beta | |
| PE20120075A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
| Sachan et al. | Basics and therapeutic potential of oral mucoadhesive microparticulate drug delivery systems | |
| US6207193B1 (en) | Transdermal drug delivery system | |
| JP2005533081A5 (no) |